Alkaline phosphatases are a group of isoenzymes, located on the outer layer of the cell membrane; they catalyze the hydrolysis of organic phosphate esters present in the extracellular space. Zinc and magnesium are important co-factors of this enzyme. Although alkaline phosphatases are present in different body tissues and have different physiochemical properties, they are true isoenzymes because they catalyze the same reaction. In the liver, alkaline phosphatase is cytosolic and present in the canalicular membrane of the hepatocyte. Alkaline phosphatase is present in decreasing concentrations in the placenta, ileal mucosa, kidney, bone, and liver. The majority of alkaline phosphatase in serum (more than 80%) is released from liver and bone, and in small amounts from the intestine. Even though alkaline phosphatases are present in many tissues throughout the body, their precise physiological function remains largely unknown.
Alkaline phosphatases are classified as tissue-specific and tissue nonspecific types. Alkaline phosphatases found in the intestine, placenta, and germinal tissue are tissue-specific. This means they are found only in the tissues where they are expressed in physiological conditions. They may also contribute to the circulating pool of serum alkaline phosphatase under specific situations when there is increased stimulation of their production. The tissue-nonspecific alkaline phosphatases form most of the fraction circulating in serum and, therefore, is of clinical interest. A single gene encodes it and is expressed in the liver, bone, and kidneys. Intestinal alkaline phosphatase is coded by a separate gene, which is different from the gene that codes for placental alkaline phosphatase and the Regan isoenzyme (produced in excess amounts in Hodgkin lymphoma). All tissue-nonspecific alkaline phosphatases have the same amino acid sequence but different carbohydrate and lipid side chains; post-translational modifications confer their unique physicochemical properties.
Serum alkaline phosphatase levels will vary with age in normal individuals. Levels are high during childhood and puberty due to bone growth and development. The decrease in level in the 15 to 50 year age group is slightly higher in men than in women. These levels rise again in old age (significant difference in gender distribution). The reasons for these normal variations are not known. Research has shown a positive correlation with body weight and smoking, and there is an inverse correlation with height.
In healthy individuals, the circulating enzyme is primarily derived from liver and bone. In some individuals, this enzyme comes from the intestinal tract to a minimal extent. In individuals with blood groups O and B, serum alkaline phosphatase levels increase after consuming a fatty meal, due to contribution from the intestinal tract. As this elevation can persist for up to 12 hours in the serum, the recommendation is to check the serum enzyme levels in a fasting state.
Alkaline phosphatase behaves like any other serum protein. It has a half-life of 7 days, and clearance from serum is independent of bile duct patency or functional capacity of the liver. However, the site of degradation of alkaline phosphatase is not known. Serum alkaline phosphatase levels may remain elevated for up to 1 week after the resolution of biliary obstruction. The liver is the source in most patients with elevated enzyme levels. Increased osteoblast activity seen in disorders of the bone or normally during periods of growth is the next likely contributor. The influx of placental alkaline phosphatase in the late third trimester contributes to the rise in pregnant women.
The mechanism of the increase in alkaline phosphatase in hepatobiliary disorders has been a matter of debate. Research has convincingly shown that it is due to increased enzyme synthesis and not to reduced hepatobiliary excretion of the enzyme. Increased hepatic enzyme activity demonstrably parallels the rise in serum alkaline phosphatase activity; this occurs primarily due to increased translation of the mRNA of alkaline phosphatase (mediated by the rising bile acid concentration) and increased secretion of alkaline phosphatase into serum via canalicular leakage into the hepatic sinusoid. The mechanism that precipitates its release into the circulation has not been elucidated. Studies report that vesicles containing alkaline phosphatase, and many such enzymes bound to the sinusoidal membranes, are found in the serum of patients with cholestasis. Because alkaline phosphatase is newly synthesized in response to biliary obstruction, its serum level may be normal in the early phase of acute biliary obstruction even when the serum aminotransferases are already at their peak.
There are several clinical methods for the determination of serum alkaline phosphatase levels. They differ by substrate used, pH of the alkaline buffer, and the “normal” values generated. The tests, in principle, rely on the ability of the enzyme to hydrolyze phosphate esters. In the most widely used international method, p-nitrophenol phosphate serves as the substrate, while an amino alcohol is used as a buffer. The rate of release of p-nitrophenol phosphate from the substrate is measurable as a marker of alkaline phosphatase activity and results are reported in international units per liter (IU/L). The different methods appear equally effective in the detection of abnormal values in various clinical diseases. Using multiples of the upper limit of normal is a simple way of comparing results obtained via different tests.
Electrophoresis does not reliably differentiate the isoenzymes as the electrophoretic mobility of bone and liver isoenzymes is only slightly different. Electrophoresis on cellulose acetate, with the addition of heat inactivation, is a much reliable test than electrophoresis alone. Polyacrylamide gel slab-based separation provides accurate identification of the liver, bone, intestinal and placental isoenzymes; this test is, however, not widely available. 
Patients with blood group O and B may need to fast before the test to avoid contribution from the intestinal isoenzyme if there is an unexplained elevation of alkaline phosphatase on routine tests. The phlebotomist uses a gold-top serum separator tube containing a clot activator and serum gel separator to collect the blood for analysis.
There are many potential analytic sources of error. Factors such as concentrations of phosphate, magnesium, citrate, type, and concentration of buffer maintenance of the correct temperature may affect the result.
When alkaline phosphatase is the only liver biochemical test that presents as elevated (i.e., when the serum aminotransferases are within normal limits), or when alkaline phosphatase is disproportionately elevated compared to other liver biochemical tests, evaluation of the patient should focus on identifying the cause and the source for the isolated or disproportionate alkaline phosphatase elevation. In asymptomatic patients with isolated elevation of serum alkaline phosphatase, it is essential to identify the primary source of abnormality. Alkaline phosphatases derived from the liver, bone, placenta, and intestines have different physicochemical properties. There are three general methods that have shown to be particularly used for discriminating between isoenzymes: thermostability studies; differential inhibition with various small peptides, amino acids, and other low molecular weight substances; and immunologic methods.
One approach utilizes the measurement of the activity of those enzymes, which increase in concordance with the liver alkaline phosphatase such as 5’-nucleotidase (5NT) and gamma-glutamyl transpeptidase (GGT). These enzymes are not elevated in disorders of bone and correlate well with hepatobiliary disorders. Serum GGT is very sensitive to biliary tract disease but is less specific for liver disorders. 5NT levels may become elevated in pregnant patients; however, in non-pregnant patients, it is relatively specific for liver disorder and correlates strongly with serum alkaline phosphatase of liver origin. However, lack of an elevated 5NT in the presence of an elevated alkaline phosphatase does not rule out hepatobiliary disease as they do not rise concomitantly in early or mild hepatic injury.
The principal clinical value of measuring serum alkaline phosphatase lies in the diagnosis of cholestatic liver disease—some of the highest elevations in alkaline phosphatases present in patients with cholestasis. Usually, four-fold of the upper limit of normal or greater elevation occurs in up to 75% of the patients with cholestasis, either intrahepatic or extrahepatic. The degree of elevation does not help distinguish the two types. Similar elevations occur in biliary obstruction due to cancer (cholangiocarcinoma, pancreatic head adenocarcinoma, or ampullary adenocarcinoma), choledocholithiasis, biliary stricture, sclerosing cholangitis, or causes of intrahepatic cholestasis such as primary biliary cholangitis, drug-induced liver injury, chronic rejection of liver allografts, infiltrative liver disease (sarcoidosis, amyloidosis, tuberculosis, and liver metastasis), severe alcoholic hepatitis causing steatonecrosis. Patients with AIDS may also have particularly high levels, either due to cholangiopathy from opportunistic infections such as cytomegalovirus, cryptosporidiosis, or granulomatous involvement of the liver from tuberculosis.
Moderate elevation (up to four times the upper limit of normal) of serum alkaline phosphatase is nonspecific as it can occur in a variety of conditions affecting the liver including cirrhosis, chronic hepatitis, viral hepatitis, congestive heart failure, and ischemic cholangiopathy. Disorders that do not primarily involve the liver such as intra-abdominal infections, cholestasis of sepsis, Hodgkin lymphoma, myeloid metaplasia, and osteomyelitis can also cause moderate elevation of serum alkaline phosphatase.
Primary or metastatic cancer raises serum alkaline phosphatase levels by local bile duct obstruction and increasing leakage of the liver isoenzyme. Primary extrahepatic cancer does not necessarily have to involve the liver or the bone; rarely, some tumors can produce their own alkaline phosphatase (Hodgkin lymphoma secreting the Regan isoenzyme) or exert a paraneoplastic effect causing leakage of the hepatic isoenzyme into the circulation (Stauffer syndrome due to renal cell carcinoma).
Abnormally low levels can be useful clinically as they are seen in Wilson's disease, especially when presenting in a fulminant form with hemolysis. Zinc is a cofactor of Alkaline phosphatase, which gets displaced by copper in Wilson's disease, a disorder of copper overload, thereby leading to low levels. Other causes of low alkaline phosphatase levels are zinc deficiency, pernicious anemia, hypothyroidism, and congenital hypophosphatasia.
An extensive evaluation is often not needed in those patients who have only a mild elevation of serum alkaline phosphatase (less than 50% elevation). Such patients may be observed clinically with periodic monitoring of serum liver biochemical tests. Whenever alkaline phosphatase levels are abnormally elevated, further evaluation should take place to determine whether the source is hepatic or non-hepatic. A hepatic source for an elevated alkaline phosphatase level is supported by the concomitant elevation of either GGT or 5NT. If the source is non-hepatic, then the evaluation of underlying undiagnosed disorder is the next step. An elevated bone alkaline phosphatase can occur in bone metastasis, Paget disease, osteogenic sarcoma, healing fractures, hyperparathyroidism, hyperthyroidism, and osteomalacia. Elevated intestinal fraction tends to occur after a fatty meal and runs in families; this does not require additional evaluation. If the liver is suspected to be the source, imaging of the biliary tree is necessary to differentiate between extrahepatic or intrahepatic cholestasis in addition to reviewing the medication list.
A right upper quadrant ultrasonography is often the first imaging study ordered. If the bile duct has become dilated, either endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP) is done depending on the clinical indication. If the bile duct does not show dilation, testing for serum antimitochondrial antibody (AMA) is the suggested next step to evaluate for primary biliary cholangitis (PBC). If serum AMA is normal, evaluation for causes of intrahepatic cholestasis, AMA-negative PBC, sarcoidosis, and various other previously mentioned disorders are necessary. Liver biopsy is often the final test employed in such situations as it helps to identify the etiology of elevated serum alkaline phosphatase.
An alkaline phosphatase test may be ordered by a health care provider as part of a routine checkup or if the patient has symptoms of a bone disorder or liver damage. Proper evaluation and classification, by the patient's healthcare team, of any abnormal alkaline phosphatase levels and related findings result in better healthcare outcomes for the patient.
|||Pinart M,Kunath F,Lieb V,Tsaur I,Wullich B,Schmidt S, Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World journal of urology. 2018 Dec 15; [PubMed PMID: 30554274]|
|||van der Doelen MJ,Mehra N,Hermsen R,Janssen MJR,Gerritsen WR,van Oort IM, Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clinical genitourinary cancer. 2018 Nov 22; [PubMed PMID: 30558834]|
|||Castells L,Cassanello P,Muñiz F,de Castro MJ,Couce ML, Neonatal lethal hypophosphatasia: A case report and review of literature. Medicine. 2018 Nov; [PubMed PMID: 30508915]|
|||Cristoferi L,Nardi A,Ronca V,Invernizzi P,Mells G,Carbone M, Prognostic models in primary biliary cholangitis. Journal of autoimmunity. 2018 Dec; [PubMed PMID: 30420264]|
|||Azpiazu D,Gonzalo S,Villa-Bellosta R, Tissue Non-Specific Alkaline Phosphatase And Vascular Calcification: A Potential Therapeutic Target. Current cardiology reviews. 2018 Oct 31; [PubMed PMID: 30381085]|
|||Brichacek AL,Brown CM, Alkaline phosphatase: a potential biomarker for stroke and implications for treatment. Metabolic brain disease. 2018 Oct 4; [PubMed PMID: 30284677]|
|||Heinrich D,Bruland Ø,Guise TA,Suzuki H,Sartor O, Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. Future oncology (London, England). 2018 Oct; [PubMed PMID: 29925281]|
|||Matsushita M,Harajiri S,Tabata S,Yukimasa N,Muramoto Y,Komoda T, [Alkaline phosphatase activity in blood group B or O secretors is fluctuated by the dinner intake of previous night]. Rinsho byori. The Japanese journal of clinical pathology. 2013 Apr [PubMed PMID: 23855186]|
|||Masrour Roudsari J,Mahjoub S, Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget's specimens. Caspian journal of internal medicine. 2012 Summer [PubMed PMID: 24009918]|
|||Pike AF,Kramer NI,Blaauboer BJ,Seinen W,Brands R, A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. Biochimica et biophysica acta. 2013 Dec [PubMed PMID: 23899605]|
|||[PubMed PMID: 27077032]|
|||[PubMed PMID: 6404566]|
|||[PubMed PMID: 832369]|
|||Sharma U,Pal D,Prasad R, Alkaline phosphatase: an overview. Indian journal of clinical biochemistry : IJCB. 2014 Jul [PubMed PMID: 24966474]|
|||Vroon DH,Israili Z, Alkaline Phosphatase and Gamma Glutamyltransferase . 1990 [PubMed PMID: 21250047]|
|||Shamban L,Patel B,Williams M, Significantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure. Gastroenterology research. 2014 Apr [PubMed PMID: 27785272]|
|||[PubMed PMID: 21994858]|
|||[PubMed PMID: 24615345]|
|||Kranidiotis GP,Voidonikola PT,Dimopoulos MK,Anastasiou-Nana MI, Stauffer's syndrome as a prominent manifestation of renal cancer: a case report. Cases journal. 2009 Jan 13 [PubMed PMID: 19144140]|
|||Shaver WA,Bhatt H,Combes B, Low serum alkaline phosphatase activity in Wilson's disease. Hepatology (Baltimore, Md.). 1986 Sep-Oct [PubMed PMID: 3758940]|
|||Verma J,Gorard DA, Persistently elevated alkaline phosphatase. BMJ case reports. 2012 Aug 24 [PubMed PMID: 22922932]|
|||[PubMed PMID: 11819442]|
|||[PubMed PMID: 28586152]|
|||[PubMed PMID: 22541695]|